Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
SE1-H5226 | Human | Human Serpin A1 Protein, His Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Alpha1-proteinase inhibitor (Human, Grifols) | TAL-6004 | Approved | Grifols Sa, Bayer AG | Prolastin | United States | alpha 1-Antitrypsin Deficiency | null | 1987-12-02 | Cystic Fibrosis; Coronavirus Disease 2019 (COVID-19); alpha 1-Antitrypsin Deficiency; Pancreatitis, Chronic; Pulmonary Emphysema | Details |
Alfalastin (LFB SA) | Approved | Lfb Biotechnologies Sas | Alfalastin | France | alpha 1-Antitrypsin Deficiency | Lfb Biotechnologies Sas | 2005-08-01 | alpha 1-Antitrypsin Deficiency | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Fazirsiran | TAK-999; ADS-001; ARO-AAT | Phase 3 Clinical | Arrowhead Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd | alpha 1-Antitrypsin Deficiency; Hepatic Insufficiency | Details |
Belcesiran | DCR-S1459; NN 6021; NN6021; DCR-A1AT | Phase 2 Clinical | Dicerna Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc | Adrenoleukodystrophy; alpha 1-Antitrypsin Deficiency | Details |
INBRX-101 | INBRX-101; AT-292; rhAAT-Fc; AAT-IgG-Fc; AAT-Fc; SAR447537; SAR-447537 | Phase 2 Clinical | Inhibrx, Arecor Ltd | alpha 1-Antitrypsin Deficiency; Emphysema | Details |
VX-864 | VX-864 | Phase 2 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
KRRO-110 | KRRO-110 | Phase 2 Clinical | Korro Bio Inc | alpha 1-Antitrypsin Deficiency | Details |
WVE-006 | WVE-006 | Phase 2 Clinical | Wave Life Sciences Ltd | alpha 1-Antitrypsin Deficiency | Details |
BEAM-302 | α1-AD; α-1-AD; BEAM-302 | Phase 2 Clinical | Beam Therapeutics Inc | alpha 1-Antitrypsin Deficiency | Details |
KB-408 | KB-408 | Phase 1 Clinical | Krystal Biotech Inc | alpha 1-Antitrypsin Deficiency | Details |
VX-668 | VX-668; VX668 | Phase 1 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
VX-634 | VX-634 | Phase 1 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
BMN-349 | BMN-349 | Phase 1 Clinical | Biomarin Pharmaceutical Inc | alpha 1-Antitrypsin Deficiency | Details |
Alpha-1 antitrypsin (Kalytera Therapeutics) | Clinical | Clalit Health Services | Details |
This web search service is supported by Google Inc.